Related references
Note: Only part of the references are listed.Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
J-C Hernandez-Boluda et al.
LEUKEMIA (2018)
Mayo CALR mutation type classification guide using alpha helix propensity
Terra L. Lasho et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis
Nicole Naumann et al.
GENES CHROMOSOMES & CANCER (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
Ayalew Tefferi et al.
LEUKEMIA (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Francesca Palandri et al.
SEMINARS IN HEMATOLOGY (2018)
Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases
Sahrish Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
MPL-mutated essential thrombocythemia: a morphologic reappraisal
Natasha Szuber et al.
BLOOD CANCER JOURNAL (2018)
Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance
Daniela Barraco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Peter Valent et al.
BLOOD (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome
Sa A. Wang et al.
HAEMATOLOGICA (2017)
Myeloproliferative Neoplasms
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies
Sandeep Mukherjee et al.
CANCER GENETICS (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome
Sa A. Wang et al.
HAEMATOLOGICA (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Ilyas Chachoua et al.
BLOOD (2016)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
Xenia Cabagnols et al.
BLOOD (2016)
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
Yoseph C. Elala et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Chronic neutrophilic leukaemia
Guldeep Uppal et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Myeloproliferative Neoplasms A Contemporary Review
Ayalew Tefferi et al.
JAMA ONCOLOGY (2015)
Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression
C. Hahm et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
G. Barosi et al.
LEUKEMIA (2015)
Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11)
A. N. Chamseddine et al.
CASE REPORTS IN HEMATOLOGY (2015)
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
What is next generation sequencing?
Sam Behjati et al.
ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION (2013)
Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms
Sangeeta Nischal et al.
CANCER RESEARCH (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Significance of cytogenetic abnormalities in patients with polycythemia vera
Matjaz Sever et al.
LEUKEMIA & LYMPHOMA (2013)
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Julia E. Maxson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
Ayalew Tefferi et al.
BLOOD (2011)
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
Chiara Elena et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
D. Caramazza et al.
LEUKEMIA (2011)
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
Kebede Hussein et al.
BLOOD (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms
Nils H. Thoennissen et al.
BLOOD (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
Constantine S. Tam et al.
BLOOD (2009)
Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan
Tomonori Hidaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
Kebede Hussein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Conventional cytogenetics in myelofibrosis: literature review and discussion
Kebede Hussein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
Matjaz Sever et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
Cytogenetic studies at diagnosis in polycythemia vera:: clinical and JAK2V617F allele burden correlates
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)
J. T. Reilly
LEUKEMIA (2008)
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
F. Cervantes et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases
Rafael Santana-Davila et al.
LEUKEMIA RESEARCH (2008)
Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications
Anna D. Panani
CANCER LETTERS (2007)
Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients
Vesna Djordjevic et al.
CANCER GENETICS AND CYTOGENETICS (2007)
Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis
D Dingli et al.
CANCER (2006)
De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia
HH Hsiao et al.
LEUKEMIA RESEARCH (2005)
JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
AP Wolanskyj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information
U Bacher et al.
ANNALS OF HEMATOLOGY (2005)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)
Karyotypic abnormalities in myelofibrosis following polycythemia vera
J Andrieux et al.
CANCER GENETICS AND CYTOGENETICS (2003)
Chronic neutrophilic leukaemia: A distinct clinical entity?
JT Reilly
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Cytogenetic studies in patients with mastocytosis
B Swolin et al.
CANCER GENETICS AND CYTOGENETICS (2000)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
